ETV6 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL2147029	0.36	7/20
SCHEMBL2147035	0.36	7/20
SCHEMBL10128578	0.61	6/20
SCHEMBL10129005	0.49	6/20
SCHEMBL2148206	0.34	6/20
SCHEMBL2147790	0.34	6/20
SCHEMBL2147395	0.32	6/20
SCHEMBL4695372	0.55	5/20
SCHEMBL4167662	0.55	5/20
SCHEMBL4171720	0.54	5/20
SCHEMBL4179850	0.54	5/20
SCHEMBL4692302	0.54	5/20
SCHEMBL4695093	0.54	5/20
SCHEMBL4171927	0.53	5/20
SCHEMBL4166019	0.51	5/20
SCHEMBL4695472	0.49	5/20
SCHEMBL4171882	0.49	5/20
SCHEMBL4695452	0.48	5/20
SCHEMBL4167319	0.48	5/20
SCHEMBL10036189	0.48	5/20

Clinical trials — most relevant to ETV6 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
A Study of Low Dose Interferon Alpha Versus Hydroxyurea in Treatment of Chronic Myeloid Neoplasms	PHASE3	COMPLETED
Role of the Therapy Tailored to Risk Factors in Treating Adult Patients (≤60) With Acute Myeloid Leukemia	PHASE3	UNKNOWN
Precision Diagnosis Directing HDACi Chidamide Target Therapy for Adult ETP-ALL	PHASE2/PHASE3	UNKNOWN
Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia	PHASE3	COMPLETED
Sympathicomimetic Agonist in Patients With Myeloproliferative Neoplasms With JAK2-mutation	PHASE2	COMPLETED
Ruxolitinib in Thrombocythemia and Polycythemia Vera	PHASE2	RECRUITING
Ibrutinib in Combination With Rituximab in Patients With Indolent Clinical Forms of MCL	PHASE2	ACTIVE_NOT_RECRUITING
Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell Leukemia	PHASE1/PHASE2	RECRUITING
Pegylated Interferon Alfa-2a Salvage Therapy in High Risk Polycythemia Vera (PV) or Essential Thrombocythemia (ET)	PHASE2	COMPLETED
Open-Label Study of Oral CEP-701 (Lestaurtinib) in Patients With Polycythemia Vera or Essential Thrombocytosis	PHASE2	COMPLETED
Selective Treatment According to Molecular Subtype of Prostate Cancer	PHASE2	UNKNOWN
Polycythemia Vera, Myelofibrosis and Essential Thrombocythemia: Identification of PV, MF & ET Genes	nan	COMPLETED
Study of Individuals and Families With Aberrations in DDX41 or Similar Cancer Predisposition Variants	nan	RECRUITING
Detection of IKZF1 Deletion Mutation in Patients With Acute Lymphoblastic Leukemia and Its Impact in Therapy	nan	UNKNOWN
Familial Myeloproliferative Disorders	nan	COMPLETED
MPN Childhood Registry	nan	RECRUITING
A ELN-Multicenter Study on Phenotypic Evolution and Clinical Outcomes	nan	RECRUITING
Combination of JAK2 Inhibitor and Erythropoiesis-stimulating Agent in Myelofibrosis	nan	COMPLETED
Functional and Phenotypic Characterization of Monocytes in Myeloproliferative Syndromes	nan	RECRUITING
PAX5-NEGATIVE HODGKIN-LIKE LYMPHOMAS: A DIAGNOSTIC CHALLANGE	nan	RECRUITING
Unveiling the Germline Predisposition to Myeloproliferative Neoplasms	nan	RECRUITING
A Treatment Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia	nan	RECRUITING
Unraveling the Role of Extracellular Vesicles-driven Senescence in Myeloproliferative Neoplasms	nan	ACTIVE_NOT_RECRUITING
CMOP Regimen and Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma	nan	UNKNOWN
Autoantibodies Against Type I Interferon in Patients Affected With Ph-negative Myeloproliferative Neoplasms (MPN-IFN Study)	nan	ACTIVE_NOT_RECRUITING
A New Diagnostic Algorithm to Non-invasively Track Fibrotic Changes in Myeloproliferative Neoplasms Based on C-C Chemokine Receptor 2 Detection. From Flow Cytometry to the Development of Targeted Positron Emission Tomography Molecular Imaging. Pre-clinical Studies and First In-human Proof of Concept	nan	RECRUITING
Long Non-coding RNAs and Their Role on Epigenome as Diagnostic Markers in Childhood Acute Lymphoblastic Leukemia of T Cells.	nan	UNKNOWN
JAK2V617F Mutated Endothelium Has a Stem Cell Potential in Primary Myelofibrosis: a New Disease Ontogenesis for Chronic Myeloproliferative Disorders	nan	COMPLETED
Next Generation Sequencing (NGS) in Familial Acute Myeloid Leukemia and Myelodisplastic Syndromes	nan	RECRUITING
Ruxolitinib in Patients With Myelofibrosis	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a ETV6 binder may also engage these)

Protein	Name	Similarity
Q0VC65	—	1.000	Q0VC65 →
P97360	—	1.000	P97360 →
Q90837	—	0.992	Q90837 →
P81270	—	0.990	P81270 →
P41157	—	0.990	P41157 →
ERG	Transcriptional regulator ERG	0.989	landscape →
Q29RS8	—	0.988	Q29RS8 →
B0FZP1	—	0.988	B0FZP1 →
Q62661	—	0.988	Q62661 →
FLI1	Friend leukemia integration 1 transcription factor	0.987	landscape →
Q7Z353	—	0.987	Q7Z353 →
Q0WPH8	—	0.987	Q0WPH8 →
Q5R7I3	—	0.987	Q5R7I3 →
P24610	—	0.986	P24610 →
ETV1	ETS translocation variant 1	0.986	landscape →
P10157	—	0.985	P10157 →
P26323	—	0.985	P26323 →
B0FZN9	—	0.985	B0FZN9 →
Q2KJ34	—	0.985	Q2KJ34 →
P46200	—	0.985	P46200 →
B0FZN8	—	0.985	B0FZN8 →
Q5HYM0	—	0.985	Q5HYM0 →
P35993	—	0.984	P35993 →
P18756	—	0.984	P18756 →
B2GUY1	—	0.984	B2GUY1 →
P41164	—	0.984	P41164 →
P06212	—	0.984	P06212 →
Q68EL6	—	0.984	Q68EL6 →
B0FZP2	—	0.984	B0FZP2 →
P06211	—	0.984	P06211 →